Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy /N. Babyshkina, E. N. Zavyalova, N. A. Tarabanovskaya [et al.]

Электронный ресурс
Другой Автор
Zavyalova, Marina V.
Tarabanovskaya, Natalia A.
Dronova, Tatyana
Krakhmal, Nadezhda V.
Slonimskaya, Elena M.
Kzhyshkowska, Julia G.
Choynzonov, Evgeny L.
Cherdyntseva, Nadezhda V.
Babyshkina, Nataliya
Источник
Molecular and cellular biochemistry 2018 Vol. 444, № 1/2. P. 197-206
Аннотация
The identification of informative biomarkers that could predict the treatment response is particularly important in the triple-negative (TN) breast cancer, which is characterized by biological diversity. The aim of this study was to investigate the impact of vascular endothelial growth factor receptor (VEGFR2) expression and its gene polymorphisms on pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in Russian patients with TN breast cancer. We performed a retrospective analysis of 70 women with operable TN breast cancer, who underwent NCT with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or cyclophosphamide, adriamycin, and capecitabine (CAX) between 2007 and 2013. VEGFR2 expression was evaluated before NCT by immunohistochemistry. TaqMan SNP assays were used for genotyping KDR − 604T>C (rs2071559) and KDR 1192G>A (rs2305948) polymorphisms. The pCR was used as an end-point in the treatment efficacy analysis. In the univariate analysis, the pCR rate was strongly associated with young age (P = 0.004), high Ki67 expression (P = 0.012), lymph node negativity (P = 0.023) as well as with positive VEGFR2 expression (P = 0.019) and the CAX regimen (P = 0.005). In the multivariate analysis, only patient’s age (P = 0.005) and pre-NCT VEGFR2 expression (P = 0.048) remained significant predictors of pCR. The pCR rate was higher in the CAX-treated patients than that in the FAC-treated patients (P = 0.005). Our results revealed that − 604TT genotype of rs2071559 and age < 50 years were correlated with a pCR in the CAX-treated patients. VEGFR2 expression in pre-NCT tumors and KDR gene polymorphism can be considered as additional predictive molecular markers of pCR in Russian TN breast cancer patients treated with NCT.
Всего оценка: 0
Нет записей для отображения.
 
 
 
03559nab a2200409 c 4500
001
 
 
vtls000651571
003
 
 
RU-ToGU
005
 
 
20190402173400.0
007
 
 
cr |
008
 
 
190329|2018    xxu     s         a eng dd
024
7
$a 10.1007/s11010-017-3244-1 $2 doi
035
$a to000651571
039
9
$a 201904021734 $b cat34 $c 201903291543 $d VLOAD $y 201903291533 $z VLOAD
040
$a RU-ToGU $b rus $c RU-ToGU
245
1
0
$a Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy $c N.  Babyshkina, E. N. Zavyalova, N. A. Tarabanovskaya [et al.]
504
$a Библиогр.: 23 назв.
520
3
$a The identification of informative biomarkers that could predict the treatment response is particularly important in the triple-negative (TN) breast cancer, which is characterized by biological diversity. The aim of this study was to investigate the impact of vascular endothelial growth factor receptor (VEGFR2) expression and its gene polymorphisms on pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in Russian patients with TN breast cancer. We performed a retrospective analysis of 70 women with operable TN breast cancer, who underwent NCT with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or cyclophosphamide, adriamycin, and capecitabine (CAX) between 2007 and 2013. VEGFR2 expression was evaluated before NCT by immunohistochemistry. TaqMan SNP assays were used for genotyping KDR − 604T>C (rs2071559) and KDR 1192G>A (rs2305948) polymorphisms. The pCR was used as an end-point in the treatment efficacy analysis. In the univariate analysis, the pCR rate was strongly associated with young age (P = 0.004), high Ki67 expression (P = 0.012), lymph node negativity (P = 0.023) as well as with positive VEGFR2 expression (P = 0.019) and the CAX regimen (P = 0.005). In the multivariate analysis, only patient’s age (P = 0.005) and pre-NCT VEGFR2 expression (P = 0.048) remained significant predictors of pCR. The pCR rate was higher in the CAX-treated patients than that in the FAC-treated patients (P = 0.005). Our results revealed that − 604TT genotype of rs2071559 and age < 50 years were correlated with a pCR in the CAX-treated patients. VEGFR2 expression in pre-NCT tumors and KDR gene polymorphism can be considered as additional predictive molecular markers of pCR in Russian TN breast cancer patients treated with NCT.
653
$a рак молочной железы
653
$a неоадъювантная химиотерапия
653
$a факторы роста эндотелия сосудов
653
$a информативные биомаркеры
655
4
$a статьи в журналах
700
1
$a Zavyalova, Marina V.
700
1
$a Tarabanovskaya, Natalia A.
700
1
$a Dronova, Tatyana
700
1
$a Krakhmal, Nadezhda V.
700
1
$a Slonimskaya, Elena M.
700
1
$a Kzhyshkowska, Julia G.
700
1
$a Choynzonov, Evgeny L.
700
1
$a Cherdyntseva, Nadezhda V.
700
1
$a Babyshkina, Nataliya
773
0
$t Molecular and cellular biochemistry $d 2018 $g Vol. 444, № 1/2. P. 197-206 $x 0300-8177
852
4
$a RU-ToGU
856
4
$u http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000651571
908
$a статья
999
$a VIRTUA               
999
$a VTLSSORT0070*0080*0240*0350*0400*2450*5040*5200*6530*6531*6532*6533*6550*7008*7000*7001*7002*7003*7004*7005*7006*7007*7730*8520*8560*9080*9992
Нет комментариев.
Предмет
статьи в журналах
Резюме
The identification of informative biomarkers that could predict the treatment response is particularly important in the triple-negative (TN) breast cancer, which is characterized by biological diversity. The aim of this study was to investigate the impact of vascular endothelial growth factor receptor (VEGFR2) expression and its gene polymorphisms on pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in Russian patients with TN breast cancer. We performed a retrospective analysis of 70 women with operable TN breast cancer, who underwent NCT with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or cyclophosphamide, adriamycin, and capecitabine (CAX) between 2007 and 2013. VEGFR2 expression was evaluated before NCT by immunohistochemistry. TaqMan SNP assays were used for genotyping KDR − 604T>C (rs2071559) and KDR 1192G>A (rs2305948) polymorphisms. The pCR was used as an end-point in the treatment efficacy analysis. In the univariate analysis, the pCR rate was strongly associated with young age (P = 0.004), high Ki67 expression (P = 0.012), lymph node negativity (P = 0.023) as well as with positive VEGFR2 expression (P = 0.019) and the CAX regimen (P = 0.005). In the multivariate analysis, only patient’s age (P = 0.005) and pre-NCT VEGFR2 expression (P = 0.048) remained significant predictors of pCR. The pCR rate was higher in the CAX-treated patients than that in the FAC-treated patients (P = 0.005). Our results revealed that − 604TT genotype of rs2071559 and age < 50 years were correlated with a pCR in the CAX-treated patients. VEGFR2 expression in pre-NCT tumors and KDR gene polymorphism can be considered as additional predictive molecular markers of pCR in Russian TN breast cancer patients treated with NCT.